MVMarisol Veny

Marisol Veny

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marisol Veny has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Azucena Salas

    Inflammatory Bowel Disease Unit, Hospital Clínic of Barcelona, Institut d’Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain

    3 shared publications
  • Alba Garrido-Trigo

    Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic, CIBEREHD

    2 shared publications
  • Albert Martin-Cardona

    Hospital Universitari Mútua Terrassa, Universitat de Barcelona

    2 shared publications
  • Julián Panés

    Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

    2 shared publications
  • Lisseth Robbins

    Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic, CIBEREHD

    2 shared publications
  • Agnès Fernández-Clotet

    Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic, CIBEREHD

    1 shared publication

Latest Publications

  • Open Access

    Specialized macrophages link gut lymphoid follicles to Crohn’s disease granulomas

    by Azucena Salas, Marc Buendia, Ángela Sanzo-Machuca, Sofia Sabate, Marisol Veny, Isabella Dotti, Victoria Gudiño, Alba Garrido-Trigo, Elisa Melon-Ardanaz, Antonio Carrasco, et al.

    Granulomas are a defining feature of Crohn’s disease associated with a more severe disease course, yet their developmental origins and cellular organization remain poorly understood. Here, we integrate single-cell and spatial transcriptomics of human intestinal tissues with in situ validation and functional macrophage assays to investigate granuloma formation. Crohn’s disease granulomas share cellular, transcriptional and spatial features with isolated lymphoid follicles, suggesting that chronic inflammation may repurpose pre-existing lymphoid structures. We identify a previously uncharacterized population of PLA2G2D-expressing macrophages enriched in isolated lymphoid follicles and at granuloma peripheries. Lymphotoxin-α1β2, LIGHT and TNF induce this macrophage programme in vitro , while TNF and low-dose lipopolysaccharide promote CXCL9 production together with PLA2G2D expression, potentially supporting effector T-cell recruitment in the granuloma environment. Conversely, SPP1-expressing macrophages preferentially occupy granuloma cores, are induced by IL-1β or hypoxia, and interact with inflammatory fibroblasts through profibrotic signalling networks. These findings define spatially and functionally distinct macrophage niches within Crohn’s disease granulomas and support a model in which inflammatory signals transform homeostatic lymphoid macrophage programmes to promote granuloma organization and fibrotic remodelling.

  • Open Access

    TL1A-activated T cells remodel the rectal mucosa in Crohn’s disease patients with perianal fistulizing disease

    by Victoria Gudiño, Jae-Won Cho, Berta Caballol, Ana M. Corraliza, Marisol Veny, Isabella Dotti, Livia Moreira Genaro, Ángela Sanzo-Machuca, Elisa Melón-Ardanaz, M. Carme Masamunt, et al.

    Background: Perianal fistulizing disease (PFD) is a complication that affects about 20% of Crohn’s disease (CD) patients whose etiology remains unknown. Objectives: To identify predisposing events driving fistula formation. Design: Rectal biopsies from CD patients with or without PFD (CD+PFD and CD, respectively; n=31) were collected and subjected to single-cell RNA sequencing (scRNA-seq). Functional analyses were conducted using peripheral CD3+ T cells, intestinal tissue explants, primary fibroblasts and 2D-epithelial monolayer cell cultures. Results: The rectal mucosa of CD+PFD patients is imprinted with cellular and transcriptomic alterations specific to PFD and independent of luminal inflammation, potentially driven by TL1A activation in CD4+ T cells. We identified lymphotoxin beta ( LTB or its functional heterotrimer LTα 1 β 2 ) as a novel mediator downstream of TL1A that, along with IL-22, induces a PFD-associated signature in rectal fibroblast and epithelial cells, respectively. This signature includes an increased abundance of fibroblasts, an induction of matrix-degrading enzymes, transcriptomic rewiring of the lamina propria S1 fibroblasts, and an anti-bacterial and immune responses in epithelial cells. Notably, the induction of LTα 1 β 2 and IL-22 occurs independently of TNF signaling, revealing a new TL1A-LTα 1 β 2 /IL-22 axis that remains active under anti-TNF therapy. Conclusion: Our findings revealed unique cellular alterations in the rectum of CD patients with PFD, highlighting the previously unrecognized involvement of TL1A in mediating this signature and supporting the need for exploring the role of TL1A inhibition as a therapeutic approach for PFD.

  • Open Access

    Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases

    by Bram Verstockt, Sare Verstockt, Marisol Veny, Jonas Dehairs, Kaline Arnauts, Gert Van Assche, Gert De Hertogh, Séverine Vermeire, Azucena Salas, Marc Ferrante